Flunixin
Flunixin is a cyclooxygenase (COX) inhibitor with IC50 values of 0.55 and 3.24 μM for COX-1 and COX-2, respectively. Flunixin shows anti-inflammatory effects.
For research use only. We do not sell to patients.
- CAS No.: 38677-85-9
- Formula: C14H11F3N2O2
- Molecular Weight:296.24
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[2]|
COX-1 0.55 μM (IC50) |
COX-2 3.24 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Bone marrow cell | EC50 |
16 μM
Compound: Flunixin
|
Induction of bone marrow cell differentiation isolated from ER-HOXA9 fusion protein expressed mouse harboring GFP-lysozyme assessed as upregulation of CD11b/MAC1 after 4 days by flow cytometry
Induction of bone marrow cell differentiation isolated from ER-HOXA9 fusion protein expressed mouse harboring GFP-lysozyme assessed as upregulation of CD11b/MAC1 after 4 days by flow cytometry
|
[PMID: 27994748] |
| THP-1 | EC50 |
>20 μM
Compound: Flunixin
|
Induction of human THP1 cell differentiation after 4 days by flow cytometry
Induction of human THP1 cell differentiation after 4 days by flow cytometry
|
[PMID: 27994748] |
| U-937 | EC50 |
>20 μM
Compound: Flunixin
|
Induction of human U937 cell differentiation after 4 days by flow cytometry
Induction of human U937 cell differentiation after 4 days by flow cytometry
|
[PMID: 27994748] |
In Vitro
flunixin meglumine (10-1000 μM, 2 h) inhibits lipopolysaccharide (LPS)-induced activity of inducible nitric oxide synthase (iNOS) in RAW 264.7 murine macrophages[2].
flunixin meglumine (10-1000 μM, 2 h) inhibits lipopolysaccharide-induced activation of nuclear factor kappa B (NfκB) in RAW 264.7 murine macrophages[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW 264.7 murine macrophages
-
Concentration:10, 100, 300, and 1000 μM
-
Incubation Time:2 hours
-
Result:Inhibited LPS-induced nitric oxide release at concentrations between 100 and 1,000 µM (P=0.01).
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male sheep injected with Carrageenan[1]
-
Dosage:1.1 mg/kg
-
Administration:Intravenous injection; 1.1 mg/kg; once
-
Result:Inhibited Carrageenan-induced exudate PGE2 formation (Emax, 100%, IC50, <0.4 nM) and serum TXB2 generation (Emax, 100%, IC50, 17 nM) for up to 32 h.
Chemical Information
-
CAS No. 38677-85-9
-
Molecular Weight 296.24
-
Formula C14H11F3N2O2
-
SMILES
O=C(C1=CC=CN=C1NC2=CC=CC(C(F)(F)F)=C2C)O
-
Synonyms
Sch 14714
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
[1]. Z Cheng, et al. Measurement of cyclooxygenase inhibition in vivo: a study of two non-steroidal anti-inflammatory drugs in sheep. Inflammation. 1998 Aug;22(4):353-66. [Content Brief]
[2]. Clare E Bryant, et al. Evaluation of the ability of carprofen and flunixin meglumine to inhibit activation of nuclear factor kappa B. Am J Vet Res. 2003 Feb;64(2):211-5. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)